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Abstract Cyclophosphamide (CP) is a widely used antineoplastic drug, which could cause
toxicity of the normal cells due to its toxic metabolites. Its urotoxicity may cause dose-
limiting side effects like hemorrhagic cystitis. Overproduction of reactive oxygen species
(ROS) during inflammation is one of the reasons of the urothelial injury. Selenoproteins
play crucial roles in regulating ROS and redox status in nearly all tissues; therefore, in this
study, the urotoxicity of CP and the possible protective effects of seleno-L-methionine
(SLM) on urinary bladder of rats were investigated. Intraperitoneal (i.p.) administration of
50, 100, or 150 mg/kg CP induced cystitis, in a dose-dependent manner, as manifested by
marked congestion, edema and extravasation in rat urinary bladder, a marked desquamative
damage to the urothelium, severe inflammation in the lamina propria, focal erosions, and
polymorphonuclear (PMN) leukocytes associated with occasional lymphocyte infiltration
determined by macroscopic and histopathological examination. In rat urinary bladder tissue,
a significant decrease in the endogenous antioxidant compound glutathione, and elevation
of lipid peroxidation were also noted. Pretreatment with SLM (0.5 or 1 mg/kg) produced a
significant decrease in the bladder edema and caused a marked decrease in vascular
congestion and hemorrhage and a profound improvement in the histological structure.
Moreover, SLM pretreatment decreased lipid peroxide significantly in urinary bladder
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tissue, and glutathione content was greatly restored. These results suggest that SLM offers
protective effects against CP-induced urinary bladder toxicity and could be used as a
protective agent against the drug toxicity.
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Introduction
Cyclophosphamide (CP) is extensively used as an antineoplastic agent for the treatment of
various cancers and as an immunosuppressive agent for organ transplantation [1]. CP has
been shown to induce severe hemorrhagic cystitis (HC) in laboratory animals [2] and in
patients receiving the drug as a part of their treatment [3]. HC is the major dose-limiting
side effect of CP [4]. The incidence of this side effect is dose dependent and can be as high
as 75% in patients receiving a high intravenous CP dose.
There have been many attempts to prevent CP-induced cystitis with the pretreatments of
different drugs, such as zinc or 2-mercaptoethane sulfonate (MESNA). This compound has
been shown to reduce, in part, the magnitude of CP-induced cystitis [5]. It is important to
elucidate the mechanism of CP-induced HC in order to minimize the toxic and dose-
limiting side effects of CP. Elimination the side effects of CP can lead to better tolerance of
the drug and a more efficient and comfortable therapy for patients in need of CP treatment
[6]. The overproduction of reactive oxygen species (ROS) and reactive nitrogen species
(RNS) during inflammation leads to considerable oxidant stress, cellular injury, and
necrosis via several mechanisms including peroxidation of membrane lipids, protein
denaturation, and DNA damage [7].
It is suggested that CP treatment of rats induces oxidative stress in the urinary bladder and
depletion of antioxidant enzyme, and the oxidative stress contributes to neutrophil infiltration
into bladder and hence inflammation [6]. Furthermore, Das et al. [8] have reported that CP-
induced testicular oxidative stress was manifested by a significant inhibition of peroxidase
and catalase enzyme activities and with high levels of malondialdehyde (MDA) and
conjugated dienes in the testis.
Numerous studies have shown that CP exposure enhances intracellular ROS production,
suggesting that biochemical and physiological disturbances may result from oxidative stress
[9]. The antioxidative defense system includes enzymes, such as glutathione peroxidase
(GPx), superoxide dismutase, catalase [10], and non-enzyme antioxidants, like carotenoids
[11] and selenium [12]. The cellular antioxidant system helps to minimize ROS-induced
tissue injury [6]. Thus, the combination of the drug delivery together with potent
antioxidant may be the appropriate approach to reduce the side effects of CP [1].
Selenium (Se) is a nutritionally essential trace element with anticarcinogenic properties.
Overexpression of Gpx has been reported to block ROS-induced apoptosis in several cell
types, suggesting that inhibition of this enzyme is closely related to apoptotic cell death
[12]. Limited data from studies in humans suggest that Se supplementation may enhance
immunity, including both humoral and cell-mediated responses [13]. It was demonstrated
that Se is a highly effective modulator of the therapeutic efficacy and selectivity of
anticancer drugs in nude mice bearing human tumor xenografts of colon carcinoma and
squamous cell carcinoma of the head and neck. Thus, the use of Se as selective modulator
of the therapeutic efficacy of anticancer drugs is new and novel [14]. Therefore, the aim of
the present study was to investigate the potential protective effect of seleno-L-methionine
(SLM) against CP-induced cystitis in rats.
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Materials and Methods
Animals
A total of 84 either sex Sprague–Dawley rats weighing 190–220 g were used for the
intraperitoneal injection of CP (Endoxan, Sigma-Aldrich, Taufkirchen, Germany; C0768)
and SLM (Sigma, Germany; S3132). Animals were given food and water ad libitium. Local
institutional animal care and use committee approved the experimental protocol.
Experimental Design
The rats were randomly divided into the following experimental groups, each including
seven animals: groups 1, 2, and 3 treated with 50, 100, or 150 mg/kg CP, respectively [15].
Groups 4 and 5 treated with 0.5 and 1 mg/kg SLM, respectively. Groups 6, 7, or 8 treated
with respective CP plus 0.5 mg/kg SLM. Groups 9, 10, or 11 were treated with respective
CP plus 1 mg/kg SLM. Group 12 is the control group that only received saline. Animal
groups and their treatments are summarized in Table 1.
Tissue Preparation and Histopathology
At the end of the experiment, the rats were weighed. Under the deeper ether anesthesia, the
animals were killed at day 7. The bladders were removed intact, evacuated of residual urine,
washed with saline, blotted dry on a filter paper, and weighed to determine the presence of
edema. The bladders were then cut into two equal pieces from the dome to the bottom. One half
was stored at −80°C to measure bladder MDA and glutathione (GSH) contents; the rest was
fixed for 24 h in 10% buffered formaldehyde. Tissues were embedded in paraffin and serial
cross-sections 4–5-µm thick were taken from each bladder and stained with hematoxylin–eosin.
All sections were examined under ×40 objective and scored for edema, hemorrhage, and
inflammation on a scale of 0 (normal) to 3 (severe changes).Mucosal ulceration was scored as 0
(normal), 1 (epithelial denuding), 2 (focal ulceration), and 3 (widespread epithelial ulceration)
[5–7, 9–16].
Malondialdehyde
MDA content was measured as described by Ohkawa et al. in 1979 [17]. Bladder tissue was
homogenized in appropriate buffers and used for the following assays. The mixture consisted
of 0.8 ml of sample (1 mg), 0.2 ml of 8.1% sodium dodecyl sulfate, 1.5 ml of 20% glacial
acetic acid adjusted to pH3.5, and 1.5 ml of 0.8% aqueous solution of 2-thiobarbituric acid.
The mixture was made up to 4 ml with distilled water and heated at 95°C for 60 min using a
glass ball as condenser. After cooling with tap water, 1 ml distilled water and 5 ml n-butanol
and pyridine mixture (15:1) were added, and the solution was shaken vigorously. After
centrifugation at 2,000×g for 10 min, the absorbance of the organic layer was measured at
532 nm. Amount of thiobarbituric reacting substances formed is calculated from standard
curve prepared using 1,1′,3,3′ tetramethoxy propane and the values expressed as nanomole
MDA per gram of tissue.
Glutathione
Tissue levels of acid-soluble thiols, mainly GSH, were determined colourimetrically
at 412 nm. Briefly, 0.5 mL of the previously prepared homogenate was added to
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0.5 mL of 5% trichloroacetic acid, and after centrifugation at 750×g for 5 min, the
supernatant (200µL) was added to a tube containing 1,750µL of 0.1 mol/L potassium
phosphate buffer, pH8, and 50µL 5,5′-dithiobis-(2-nitrobenzoic acid) reagent. Tubes
were mixed, and the yellow color developed was measured against a standard curve of
GSH. The protein thiol (protein-SH) content was expressed as micromole per gram of
tissue [16].
Statistics
The results were expressed as means±SEM and p<0.05 accepted as statistically significant.
Statistical analysis was performed using one-way analysis of variance for MDA and GSH
levels, body, and bladder weights. Histopathological score points were analyzed first by
using the non-parametric Kruskal–Wallis test to discover whether there was any difference
between groups. The Tukey honestly significantly different test was then performed to
analyze two groups consecutively.
Results
All histological parameters and urinary bladder weights are summarized in Table 2. Three
doses of CP (groups 1, 2, and 3) induced acute urinary bladder damage. This was
manifested by a significant increase in urinary bladder weight as a ratio of bodyweight,
reaching a more than fourfold (exclude group 1) increase with marked edema. Control
animals had histologically normal bladders with assigned scores of “0” for all four
conditions, edema, hemorrhage, inflammation, and ulceration. Severe histological changes
and higher grades of hematuria were observed for animals receiving CP (groups 2 and 3),
and severe ulceration and erosion was encountered, as shown in Fig. 1. In addition,
histological examination revealed that CP induced extensive inflammation of the lining
urothelium, petechial hemorrhage in the lamina propria associated with proteinaceous
Table 2 Comparison of Histological Damage and Bladder/Body Weight (blw/bw) Ratio of Rat Bladders
[Median (Min–Max)]
Groups (mg/kg) Edema Hemorrhage Inflammation Ulceration Total damage blw/bw (mg/g)
Control 0 0 0 0 0 0.53 (0.42–0.68)
50 CP 7 0 3 3 13 0.77* (0.67–0.88)
100 CP 17* 5 11 11 42* 2.12* (1.89–2.43)
150 CP 19* 8* 12* 15* 54* 2.39* (1.99–2.77)
0.5 SLM 0 0 0 3 3 0.51 (0.40–0.66)
1 SLM 0 0 0 4 4 0.48 (0.43–0.71)
50 CP +0.5 SLM 0 0 0 0 0 0.56* (0.41–0.70)
100 CP+0.5 SLM 4 1 3 3 11 0.85** (0.68–1.12)
150 CP+0.5 SLM 3 3 4 6 16 0.83** (0.65–1.11)
50 CP+1 SLM 2 0 0 8 10 0.62* (0.47–0.84)
100 CP+1 SLM 7 3 7 8 25 0.72** (0.58–0.98)
150 CP+1 SLM 1 3 0** 5 9 0.67** (0.51–0.83)
*p<0.05 compared with control group; **p<0.05 compared with CP group
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material infiltrating into the lumen and infiltration of erythrocytes, desquamative epithelium
as well as PMN leukocytes with focal erosions of the urinary bladder. Pretreatment with
SLM (groups 6, 7, 8, 9, 10, and 11) caused a significant decrease in urinary bladder weight
(Table 2) and markedly decreased the vascular congestion and hemorrhage and resulted in a
profound improvement in the histological structure of the urinary bladder (Figs. 2 and 3).
SLM alone caused slight histopathological changes (ulceration) in the normal structure of
the urinary bladder (Table 2).
CP injection resulted also in increased MDA levels (two- to fivefold) and decreased GSH
levels (by 64%), indicating that oxidative stress was present in the bladders. Pretreatment with
SLM ameliorated CP-induced cystitis, as indicated by a significant decrease in lipid peroxides
(MDA) and a marked increase of antioxidant (GSH) levels (Figs. 4 and 5).
Discussion
HC is a major therapy-limiting side effect of CP. The main features of HC are urothelial
damage, transmural edema, hemorrhage, mucosal ulceration, and epithelial necrosis. These
can be demonstrated within 24 h of a single dose [18]. The urotoxicity of CP is thought to
be due to the formation of acrolein that damages the urothelium [19, 20]. In accordance
Fig. 1 Representative light micrographs showing bladder histology. a Bladder taken from the control rats
showing normal histology. b A bladder section of a CP 50-treated rat showing edema in the connective tissue
and condensed nuclei (arrow) in some epithelial cells. c A bladder section taken from a CP 100-treated rat
showing interruptions in the epithelium. There are hemorrhage and edema in the connective tissue. d A
bladder section of a CP 150-treated rat showing epithelial disappearance with edema and hemorrhage in the
connective tissue
Protective Effect of SLM on CP-Induced Urinary Bladder Toxicity in Rats 103
with other studies, the damage caused in this study by CP to the structure of the bladders
increased as the dose rose. Similarly structural damage was obtained when 100 mg/kg CP
was injected to rats [5]. In the present study, treatment with CP produced marked
congestion and edema in rat bladder. Histopathological examinations also showed petechial
hemorrhage and inflammatory reaction in the lamina propria of the urinary bladder and
proteinaceous material in the lumen. PMN leukocytes with occasional lymphocyte
infiltration and focal erosions were also observed in urinary bladders from CP-treated rats.
These results are consistent with those of previous studies reporting that CP caused
excessive protein extravasation, vascular congestion, and edema of the bladder and
extensive leukocyte production of NO [21, 22].
HC is now accepted as a non-microbial inflammation, and the pathogenesis of HC may
be summarized as cytokine production leading to inducable nitric oxide synthase (iNOS)
induction. There is evidence that urinary bladder epithelial cells express reactivity to iNOS
in the cytoplasm, leading to peroxynitrite production [22]. Increased NO production is
probably responsible for the cystitis because S-methylisothiourea (an iNOS-selective
inhibitor) almost abolishes CP-induced bladder damage [11]. This improvement is thought
to result from a decrease in NO production. In addition, CP produced a decrease in the
endogenous antioxidant compound GSH and an elevation of lipid peroxidation in urinary
bladder [16, 18–22]. Our findings are in agreement with those of these studies, in which
there was a significant depletion of GSH pool and a significant increase in lipid peroxides
Fig. 2 Representative light micrographs showing bladder histology. Sections showing normal histology
from; a SLM 0.5-treated, b a SLM 0.5-+CP 50-treated rat. c Bladder taken from a SLM 0.5-+CP 100-treated
rat showing a thin, discontinuous epithelium and edema in the connective tissue. d A bladder section from a
SLM 0.5-+CP 150-treated rat showing a partially thin, discontinuous epithelium but no hemorrhage and
edema in the connective tissue
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Fig. 3 Representative light micrographs showing bladder histology. A section from a SLM 1-treated rat showing
a mild ulceration. b SLM 1-+CP 50-treated rat showing a mild discontinuous epithelium and a mild edema in
the connective tissue. c SLM 1-+CP 100-treated rat showing mild changes in the epithelium and edema in the
connective tissue. d SLM 1-+CP 150-treated rat showing a mild discontinuous epithelium and edema in the
connective tissue
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Fig. 4 MDA levels of the blad-
der. CP administration severely
increased MDA in groups 1, 2,
and 3 (51%, 77%, and 83%,
respectively, p<0.001). CP and
SLM decreased MDA level in
groups 6, 7, and 9 nearly to the
level of the control group's
(p>0.05). In group 8, MDA level
was increased by60% compared
to the control (p<0.001), whereas
decreased by 58% compared to
group 3 (p<0.001). In group 10,
MDA level was increased by
36% compared to the control
(p<0.01) and found to be de-
creased by64% compared to
group 2 (p<0.001). In group 11,
MDA level was increased by66%
compared to the control
(p<0.001) and found to be de-
creased by 51% compared to the
third group (p<0.001)
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(MDA) in urinary bladder tissues after CP injection. Similarly, it was reported that CP
produced a marked decrease in urinary bladder GSH content [23]. GSH is the major cellular
sulphydryl compound that serves as both a nucleophile and an effective reductant by
interacting with numerous electrophilic and oxidizing compounds. It can act as a non-
enzymic antioxidant by direct interaction of –SH group with ROS, or it can be involved in
the enzymatic detoxification reaction for ROS, as a cofactor or coenzyme. The depletion of
GSH content may be attributed to the direct conjugation of CP and its metabolites with free
or protein bound –SH groups [24], thereby interfering with the antioxidant functions.
Decreased GSH content can explain the additional decreased concentration of vitamin C,
which enters the cell mainly in the oxidized form where it is reduced by GSH [25]. Besides
other protective drugs, recently, amifostine and glutathione were reported to prevent
acrolein-induced HC in mouse bladder; however, the efficacy of these agents in humans has
yet to be determined [26].
Previous studies have shown that CP toxicity is associated with oxidative cell damage [27];
thus, therapeutic strategies aim to limit free radical-mediated urinary bladder injury [28].
Se is recognized to have a capacity for conferring tolerance to the toxic manifestations of
various heavy metal exposures, including cadmium, mercury, lead, and arsenic [29, 30] in
addition to role as an anticancer agent [31]. Moreover, Se has protective effects against
mercury toxicity in rat kidney and Se also used to diminish the toxic effects of the cadmium
on the antioxidant enzyme system, which in turn affects the membranes structures such as
mitochondria and endoplasmic reticulum. On the other hand, Se deficiency reducing GPx
activity has been reported in diet of glomerular disease and in diet of tubular epithelium in
normal rats [32]. Concurrent or prior injections of Se were found to protect against many of
the acute effects of cadmium, e.g., testicular necrosis, placental hemorrhage, teratogenecity,
and damage to the lactating mammary glands [14–16, 18–31, 33].
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GSH levels were found to be
decreased dose dependently only
in the first three groups that
received CP alone compared to
the control. This reduction (25%)
was not statistically significant in
group 1 (p>0.05); in groups 2
(46%) and 3 (64%), the reduction
was statistically significant
(p<0.001). When administrated
with CP, SLM raised the antiox-
idant GSH levels in group 6 by
53%, group 7 by 45%, group 9
by 51%, and in group 10 by 36%,
and these were found to be
statistically highly significant
(p<0.001); in group 8, it raised
the GSH level significantly (26%,
p<0.01). The increase in the
antioxidant GSH levels in group
11 (% 23) was not found to be
statistically significant (p>0.05)
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Olas and Wachowicz [34] has reported that the administration of sodium selenite appears
to reduce cisplatin toxicity without inhibiting the antitumor activity of cisplatin. Weijl et al.
[35] have found that supplementation with a higher dose of Se in combination with other
antioxidants (vitamins C and E) could correlate with cisplatin-induced autotoxicity and
nefrotoxicity. While the deprivation of Se can reduce the protection against oxidative stress
and impair immunocompetence, certain cancer cells appear to have acquired a selective
survival advantage that is apparent under conditions of Se deficiency and oxidative stress
[36].
The evidences obtained from our study indicate that pretreatment with SLM ameliorates
CP-induced cystitis because it leads to a reduction in the macroscopic changes induced by
CP, such as hemorrhage and edema, as well as a profound improvement in the histological
structure and shape. Both SLM doses that we used improved bladder morphology in a dose
dependent manner. SLM also offers marked protection against extensive CP-induced
inflammation. Furthermore, pretreatment with SLM ameliorated CP-induced cystitis, as
indicated by a significant decrease in MDA and a marked increased of antioxidant GSH
levels in bladder tissue. All histopathological examinations and biochemical measurements
suggest that Se may have a role in two stages, namely, prevention and interception, of
defense against ROS and RNS production.
In essence, the results of the present study suggest that CP-induced cystitis is related to
oxidative stress and ROS formation owing to depletion of GSH and/or inflammation. Se
can also protect the structure and function of the urinary bladder against CP-induced
oxidative stress. Our findings suggest that, at convenient concentration, selenium could be a
potentially effective drug in the treatment of CP-induced cystitis. We believe that additional
experimentation should be performed to explore the underlying mechanism of Se protection
against CP toxicity.
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